Fragmented Competitive Landscape The T2D market is moderately fragmented, with multiple generics, biosimilars, and branded therapies competing for share
The so-called incretin effect describes the phenomenon that orally ingested glucose leads to a much higher insulin response than intravenously administered glucose
Start your intake How GLP-1 Medications May Influence Lipid Metabolism GLP-1 receptor agonists work through multiple mechanisms that can indirectly affect lipid levels
This assertion stems from a biopsychosocial framework [19], i.e., that a GLP-1 agonist-associated reduction in appetite for food may be associated with a diminished desire for all hedonistic activities, including sex, a biological assumption rooted in serotonergic neural circuitry
GLP-1RAs currently available on the market include semaglutide (sold as Ozempic and Rybelsus), liraglutide (Victoza), dulaglutide (Tulicity), exenatide ( Byetta and Bydureon ), and tirzepatide ( Mounjaro )